Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion type Assertion NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_head.
- NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion description "[The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_provenance.
- NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion evidence source_evidence_literature NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_provenance.
- NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion SIO_000772 11414631 NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_provenance.
- NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion wasDerivedFrom befree-2016 NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_provenance.
- NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_assertion wasGeneratedBy ECO_0000203 NP321418.RAJhnX49TGRt6qA9myeOmFCoy8CrK8Qw_YB_GvFW_ia0c130_provenance.